Analysts Set Establishment Labs Holdings Inc. (NASDAQ:ESTA) PT at $78.86

Shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA) have been given a consensus recommendation of “Moderate Buy” by the eight research firms that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and six have assigned a buy recommendation to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $78.8571.

Several analysts have weighed in on ESTA shares. BTIG Research boosted their target price on shares of Establishment Labs from $81.00 to $86.00 and gave the stock a “buy” rating in a research report on Wednesday, December 31st. Needham & Company LLC reiterated a “buy” rating and set a $84.00 price objective on shares of Establishment Labs in a research note on Monday, January 12th. Wall Street Zen raised shares of Establishment Labs from a “sell” rating to a “hold” rating in a report on Sunday, October 19th. Weiss Ratings restated a “sell (e+)” rating on shares of Establishment Labs in a research note on Monday, December 29th. Finally, JPMorgan Chase & Co. lifted their price target on Establishment Labs from $71.00 to $80.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 17th.

Hedge Funds Weigh In On Establishment Labs

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Geode Capital Management LLC increased its holdings in shares of Establishment Labs by 1.2% during the 2nd quarter. Geode Capital Management LLC now owns 25,917 shares of the company’s stock valued at $1,105,000 after purchasing an additional 299 shares in the last quarter. Patriot Financial Group Insurance Agency LLC grew its position in Establishment Labs by 5.2% during the second quarter. Patriot Financial Group Insurance Agency LLC now owns 6,025 shares of the company’s stock valued at $257,000 after buying an additional 300 shares during the period. Private Advisor Group LLC increased its holdings in Establishment Labs by 14.1% in the third quarter. Private Advisor Group LLC now owns 5,450 shares of the company’s stock valued at $223,000 after buying an additional 675 shares in the last quarter. CWM LLC increased its holdings in Establishment Labs by 45.9% in the second quarter. CWM LLC now owns 2,182 shares of the company’s stock valued at $93,000 after buying an additional 686 shares in the last quarter. Finally, Quarry LP purchased a new position in Establishment Labs in the third quarter valued at $34,000. Institutional investors and hedge funds own 72.91% of the company’s stock.

Establishment Labs Stock Up 2.3%

Shares of Establishment Labs stock opened at $67.51 on Wednesday. The company has a quick ratio of 2.10, a current ratio of 3.33 and a debt-to-equity ratio of 15.06. The company has a market cap of $1.96 billion, a P/E ratio of -23.77 and a beta of 0.92. The firm’s 50 day moving average price is $69.83 and its 200-day moving average price is $52.40. Establishment Labs has a 52-week low of $26.56 and a 52-week high of $78.24.

Establishment Labs (NASDAQ:ESTA) last issued its quarterly earnings data on Wednesday, November 5th. The company reported ($0.38) EPS for the quarter, beating the consensus estimate of ($0.54) by $0.16. Establishment Labs had a negative return on equity of 235.45% and a negative net margin of 43.45%.The firm had revenue of $53.78 million during the quarter, compared to analyst estimates of $52.28 million. During the same quarter in the prior year, the business posted ($0.59) EPS. The business’s revenue for the quarter was up 33.8% compared to the same quarter last year. On average, sell-side analysts predict that Establishment Labs will post -2.41 EPS for the current fiscal year.

About Establishment Labs

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.